Paradigm Shift Therapeutics

Paradigm Shift Therapeutics (PSTx) was founded in 2014 with a mission to develop transformational and affordable cancer therapies using a lean proof of concept approach. The company's ongoing collaboration with Dr. David Roberts at the NCI is focused on developing novel CD47-targeting inhibitors, a target with the potential to radically change cancer treatment. The team, led by Teresa Burgess, Ph.D., Kate Farrell, Ph.D., and Thomas Miller, Ph.D., aims to develop inhibitors of CD47 that can be translated into clinical practice for the treatment of cancer patients. PSTx operates in the biotechnology industry. Despite the lack of publicly available information on its headquarters and last investment details, the company's focus on pioneering cancer therapies with eminent researchers positions it as an intriguing prospect for future investment.